Nadeem Riaz
@xrtGenomics
Followers
2K
Following
16K
Media
75
Statuses
2K
Physician/Scientist. Head and Neck Oncologist (radiation) & Computational Biologist. Interests in cancer genomics, immunotherapy & DNA repair. @MSKCancerCenter
New York, NY
Joined May 2009
🧵 Paradigm-buster just out: ATM-deficient tumors stay cold ❄️—unlike other DNA-repair defects—so PD-1 blockade alone (or with ATRi) falls flat. We mapped the biology in mice + patients. Paper in @JITCancer now (link below) -- #ImmunoOncology #DNArepair @OncoAlert (1/9)
4
14
44
Latest genomic AI models report near-perfect prediction of pathogenic variants (e.g. AUROC>0.97 for Evo2). We ran extensive independent evals and found these figures are true, but very misleading. A breakdown of our new preprint: 🧵
8
114
459
Congrats to Matthew McMillan @MSKCancerCenter @MSK_RadOnc #WCLC25 on presenting the secondary analysis of #CURB trial, highlighting the importance of tumor volume burden in prognosis. @xrtGenomics
6
24
59
It was such a pleasure to read the results of this juicy and terrific randomized trial of postop RT dose de-escalation for HPV+ OPSCC from @DanielMaMD and colleagues at @MayoRadOnc. The field has been waiting for the formal results, and this paper does not disappoint.
8
14
47
Led by fellow Dr. John Matthew & supervised by Dr. Phil Wong, our group examined risk factors and survival impact of severe radiation-related late toxicities in head and neck cancer–a cohort study. @LancetRH_Americ
https://t.co/OweLZMvQXP
2
11
43
Great to see this out finally🔥 Successful integration of a targeted agent (olaparib) with #radiotherapy in extensive stage SCLC👍 These trials difficult to do‼️ (we failed to commence PARPi + chemoRT trial☹️) @BenLok @SalmaJabbour1 @MGHThoracicOnc
https://t.co/l3v2hGKyXI
aacrjournals.org
Abstract. Purpose: Patients with extensive-stage small cell lung cancer (ES-SCLC) are commonly treated with induction systemic therapy and consolidative thoracic radiation therapy (TRT). PARP...
0
9
23
💡 Cancer cells don’t just mutate—they reorganize their DNA in 3D space. Our new study shows how the genome’s folding pattern shifts as tumors progress, cell by cell 🧩🧬. It’s the first 3D genome atlas of cancer progression. Thread 👇
11
81
289
It makes no sense that safety data (e.g. adverse events) for failed drugs are not made publicly available. This would be a huge resource for retrospective analysis.
The FDA is sitting on a goldmine of drug development data — 10,000+ page dossiers detailing how drugs are designed, made, tested, and approved. Big Pharma has these in-house. Startups? Locked out. It’s time to fix that. Read my proposal for @IFP on how. https://t.co/rPrLuG7tHz
4
13
118
This R packages can transform any plot using color pallets from painting at the Museum of Modern Art in New York https://t.co/rUEaPru7N3
3
43
181
How well does AI based assessment of mutations in DNA repair genes in cancer work -- we took a look 👇 great work by @ShuYazaki and team.
1/ 🧬Our paper is out @JCOPO_ASCO! We tested AlphaMissense(an AI tool for predicting the pathogenicity of missense mutations), across DNA damage repair genes in cancer. Key finding: accuracy varies dramatically by gene - crucial for clinical use! ➡️
0
2
10
Oof. Polygenic scores for IQ lose 75% of their explained variance when adding family controls, even worse than the attenuation for Educational Attainment. These are the scores Silicon Valley is using to select embryos 😬. A few thoughts on this study ...
68
267
3K
In @JCO_ASCO, our reflections on the timely ASCO TORS guideline @imrtlee @xrtGenomics 💡Encourage MR (r/o T4+ENE) & PET (r/o contra in N+) 💡Promote ND qual (min # nodes), ⬇️ bilat ND (morbid) 💡Caution re: ❌chemo 2/2 ENE degree & real-world use of frozens re margin status
3
9
29
Led by Drs. Zakeri & @imrtlee, we report early @MSK_RadOnc exp w/ 40 Gy ENI + CCRT for larynx, HPX, p16- OPX + CUP, 97.3% platinum, no uninvolved 1B+5 ☑️73 pts, f/u 23 months ✅no solitary elective failures, all LRF include 70 Gy failures ✅good QoL 👉 https://t.co/MLYwEO0PIN
1
12
34
👀Using an autonomous agent based on o3-mini and GPT-4.1, a team from Harvard, MIT & other institutions reproduced and updated an entire issue of Cochrane Reviews in two days… saving 12 person-years of work! The AI reviews captured more papers & were more accurate than humans.
41
361
2K
🚨🚨🚨 pembro in localized hnscc is finally approved !
BREAKING🚨: @US_FDA Approves Perioperative Pembrolizumab for Resectable, Locally Advanced HNSCC #oncology
https://t.co/z8IxZu74K6
0
1
7
What changed in E3311 long-term data? ✔️Transoral surgery + 50 Gy = durable control in intermediate-risk HPV+ OPC ✔️No OS or PFS difference by smoking or subsite ⚠️Observation alone in N1? Late recurrences → risky 🔑Pathologic risk-based adjuvant therapy works
3
3
5
AI-based tumor board! This space is evolving so fast.... this is a great paper on whats about to come very soon, and very widely....
Very happy to share our new paper on LLM-based tumor board agents. Submitted August 2024, published in @NatureCancer today ☺️ Led by @Dykex6
0
0
3
Funny how two of the more interesting pieces of data at #ASCO25 have little to do with extraneous medications per se, but rather the body’s circadian rhythm and physiology: 1: Exercise after surgery 2: Checkpoint inhibitors in the morning
6
66
258
👋🚨NIVOPOSTOP GORTEC #ASCO25 ‼️adj nivo x1 ➡️concurrent nivo-CRT➡️ nivo improved DFS (mostly LRC). Waiting for OS results.
7
12
28
🔔Exciting results of adj cancer directed vaccines for high risk respected HPVneg HNSCC. #ASCO25 Congrats to the investigators for this novel work.
1
4
9